{"id":"W3204212303","doi":"10.1016/j.annonc.2021.08.622","title":"339TiP SOLTI-1502 ARIANNA: Targeting PAM50 HER2-enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative metastatic breast cancer","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Genentech; Oncolytics Biotech; Eisai; Daiichi-Sankyo; Astellas Pharma US; Roche; Seagen; Puma Biotechnology; Novartis; Les Laboratories Pierre Fabre; Eli Lilly and Company; AstraZeneca; Daiichi Sankyo Europe; Breast Cancer Research Foundation; Amgen; Pfizer","keywords":"Enzalutamide; Medicine; Androgen receptor; Internal medicine; Tamoxifen; Oncology; Breast cancer; Estrogen receptor; Cancer research; Prostate cancer; Population; Exemestane; Cancer; Endocrinology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001071139,0.0002768232,0.0003716573,0.0001458858,0.0001440541,0.0003961752,0.0003084983,0.0002901902,0.003791699],"category_scores_gemma":[0.00008738201,0.0001204752,0.000224248,0.0001466781,0.0001479273,0.0002039053,0.000204528,0.0008407015,0.001013024],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003479173,"about_ca_system_score_gemma":0.0003369975,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001137182,"about_ca_topic_score_gemma":0.003698171,"domain_scores_codex":[0.9999454,0.000007494684,0.000002540789,0.000008639591,0.000008639749,0.00002732087],"domain_scores_gemma":[0.9999849,0.000001685697,0.000002288486,0.000001704101,0.000002067449,0.000007443309],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.008300484,0.002026561,0.001870189,0.0009372948,0.0002659031,0.0007995416,0.0001395209,0.003103141,0.6641845,0.00216602,0.02181273,0.2943941],"study_design_scores_gemma":[0.007314944,0.03156839,0.02362203,0.0002935578,0.0007889365,0.007843509,0.0003088118,0.01538266,0.6748059,0.001308703,0.2366058,0.0001567874],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9498281,0.0201242,0.00276681,0.001292532,0.0004296657,0.0002747118,0.0009875259,0.0008992116,0.02339728],"genre_scores_gemma":[0.9791813,0.007303743,0.002114179,0.0005856191,0.0000659294,0.0001422487,0.001247453,0.00006207858,0.009297421],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003791699,"threshold_uncertainty_score":0.01268446,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03930127710637511,"score_gpt":0.3517432248888993,"score_spread":0.3124419477825242,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}